公开(公告)号：US20230263830A1

公开(公告)日：2023-08-24

申请号：US18173159

申请日：2023-02-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61K38/08 ,  A61K39/12 ,  A61K39/39 ,  A61K39/001102 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/5434 ,  C07K16/244 ,  C07K16/2818 ,  C07K16/2821 ,  C12N5/0636 ,  A61K45/05 ,  A61K2039/5156

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241112A1

公开(公告)日：2023-08-03

申请号：US18170690

申请日：2023-02-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241111A1

公开(公告)日：2023-08-03

申请号：US18166936

申请日：2023-02-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Oliver SCHOOR ,  Claudia TRAUTWEIN ,  Norbert HILF ,  Steffen WALTER ,  Harpreet SINGH

IPC: A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  A61K39/00 ,  C07K14/47 ,  C07K14/495 ,  C07K14/725 ,  C07K16/40 ,  C07K19/00 ,  C12N9/02 ,  C12N9/10 ,  C12N5/0783

CPC classification number: A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  A61K39/0011 ,  C07K14/47 ,  C07K14/495 ,  C07K14/7051 ,  C07K16/40 ,  C07K19/00 ,  C12N9/0036 ,  C12N9/13 ,  C07K14/4748 ,  C12N5/0638 ,  A61K38/00

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US20230241109A1

公开(公告)日：2023-08-03

申请号：US18164413

申请日：2023-02-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230235014A1

公开(公告)日：2023-07-27

申请号：US18052738

申请日：2022-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/06 ,  C12N9/64 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  C07K7/02 ,  G01N33/50 ,  G01N33/566 ,  C07K16/18 ,  A61K38/08 ,  C07K14/725 ,  G01N33/569 ,  A61K38/17 ,  C12Q1/6886 ,  A01N37/46

CPC classification number: C07K14/70539 ,  A61K38/06 ,  C12N9/6491 ,  C12N5/0636 ,  C07K16/30 ,  C07K14/4748 ,  A61K39/0011 ,  C07K16/2833 ,  A61K45/06 ,  C07K14/001 ,  C07K7/06 ,  C07K7/02 ,  G01N33/505 ,  G01N33/566 ,  G01N33/5088 ,  A61K39/0005 ,  C07K16/18 ,  C07K14/47 ,  C12N5/0638 ,  A61K38/08 ,  C07K14/7051 ,  G01N33/56972 ,  C07K14/4702 ,  A61K38/1774 ,  C12Q1/6886 ,  G01N33/56977 ,  A01N37/46 ,  C07K2317/34 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/7051 ,  A61K2039/54 ,  G01N2333/70539 ,  C07K2317/31 ,  C07K2317/24 ,  G01N2333/70503 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2502/11 ,  A61K2039/572 ,  G01N2333/47 ,  C12N2501/998 ,  C12Y304/24 ,  A61K2039/57 ,  A61K2039/585 ,  A61K38/00

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20230226162A1

公开(公告)日：2023-07-20

申请号：US18160420

申请日：2023-01-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Linus BACKERT ,  Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C07K7/06 ,  C07K16/2833 ,  C07K16/30 ,  A61K2039/5158 ,  C07K2317/32

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230203127A1

公开(公告)日：2023-06-29

申请号：US18054695

申请日：2022-11-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/06 ,  C12N9/64 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  C07K7/02 ,  G01N33/50 ,  G01N33/566 ,  C07K16/18 ,  A61K38/08 ,  C07K14/725 ,  G01N33/569 ,  A61K38/17 ,  C12Q1/6886 ,  A01N37/46

CPC classification number: C07K14/70539 ,  A61K38/06 ,  C12N9/6491 ,  C12N5/0636 ,  C07K16/30 ,  C07K14/4748 ,  A61K39/0011 ,  C07K16/2833 ,  A61K45/06 ,  C07K14/001 ,  C07K7/06 ,  C07K7/02 ,  G01N33/505 ,  G01N33/566 ,  G01N33/5088 ,  A61K39/0005 ,  C07K16/18 ,  C07K14/47 ,  C12N5/0638 ,  A61K38/08 ,  C07K14/7051 ,  G01N33/56972 ,  C07K14/4702 ,  A61K38/1774 ,  C12Q1/6886 ,  G01N33/56977 ,  A01N37/46 ,  C07K2317/34 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/7051 ,  A61K2039/54 ,  G01N2333/70539 ,  C07K2317/31 ,  C07K2317/24 ,  G01N2333/70503 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2502/11 ,  A61K2039/572 ,  G01N2333/47 ,  C12N2501/998 ,  C12Y304/24 ,  A61K2039/57 ,  A61K2039/585 ,  A61K38/00

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20230125179A1

公开(公告)日：2023-04-27

申请号：US17871724

申请日：2022-07-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230100686A1

公开(公告)日：2023-03-30

申请号：US17860840

申请日：2022-07-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K14/74 ,  C07K16/30 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/10 ,  A61K39/00 ,  C12N15/115 ,  G01N33/574 ,  A61P35/00 ,  C07K16/28 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230094790A1

公开(公告)日：2023-03-30

申请号：US17937285

申请日：2022-09-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.